Details

Autor(en) / Beteiligte

• Montalescot, Gilles
• White, Harvey D
• Gallo, Richard
• Cohen, Marc
• Steg, P. Gabriel
• Aylward, Philip E.G
• Bode, Christoph
• Chiariello, Massimo
• King, Spencer B
• Harrington, Robert A
• Desmet, Walter J
• Macaya, Carlos
• Steinhubl, Steven R

Titel

Enoxaparin versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention

Ist Teil von

• The New England journal of medicine, 2006-09, Vol.355 (10), p.1006-1017

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• Unfractionated heparin has been the standard anticoagulant used during percutaneous coronary intervention (PCI). In this trial, adjusted-dose unfractionated heparin was compared with enoxaparin in patients undergoing PCI. Enoxaparin significantly reduced the rate of major bleeding. The effect on prevention of coronary events was not definitively assessed. Unfractionated heparin was compared with enoxaparin in patients undergoing PCI. Enoxaparin significantly reduced the rate of major bleeding. The American College of Cardiology, the American Heart Association, and the European Society of Cardiology recommend the use of intravenous unfractionated heparin, with the dose adjusted for the activated clotting time, during percutaneous coronary intervention (PCI). 1 , 2 However, better anticoagulation regimens are needed for PCI, given the limitations of unfractionated heparin, which include its sometimes difficult-to-manage effects on coagulation, the need for repeated monitoring of coagulation, the narrow therapeutic window, the potential induction of platelet activation, and the risk of thrombocytopenia. 3 The use of low-molecular-weight heparins as anticoagulants is increasing in patients with acute coronary syndrome who undergo PCI 4 – . . .